Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors

Kenji Kawada, Koji Murakami, Takashi Sato, Yoshiki Kojima, Hiromichi Ebi, Hirofumi Mukai, Makoto Tahara, Kaoru Shimokata, Hironobu Minami

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: To evaluate the role of FDG-PET in assessing anti-tumor efficacy of molecular targeted drugs, we prospectively performed FDG-PET and CT for response evaluation in patients treated with lapatinib, a dual inhibitor of ErbB1 and ErbB2 tyrosine kinases. Methods: Lapatinib was given orally once a day at doses ranging from 1200 to 1800 mg in a phase I study. CT and FDG-PET were performed before treatment, and at 1, 2 and 3 months after the initiation of the treatment and every 2 months thereafter. Results: A total of 29 FDG-PET examinations were performed in eight patients with various solid tumors and the metabolic activity in the tumor was evaluated as SUVmax. The best responses, as assessed by CT, were as follows; one partial response, four stable disease and three disease progression. The partial response was observed in a patient with trastuzumab-resistant breast cancer, whose SUVmax was decreased by 60% from baseline. In all of the four patients whose best response was stable disease, the SUVmax was decreased by 6-42% one month after the start of treatment. Prolonged stable disease (10 months) was observed in a patient with colon cancer, whose SUVmax was decreased by 42%. In the patient group with disease progression, SUVmax was increased in two out of three patients. Conclusions: FDG-PET detected decreases in the metabolic activity of the tumors in patients who experienced clinical benefits on treatment with lapatinib. Thus, FDG-PET may be useful for the evaluation of molecular targeted drugs, such as lapatinib.

Original languageEnglish
Pages (from-to)44-48
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume37
Issue number1
DOIs
Publication statusPublished - 2007 Jan
Externally publishedYes

Fingerprint

Positron-Emission Tomography
Protein-Tyrosine Kinases
Prospective Studies
Neoplasms
Disease Progression
lapatinib
Therapeutics
Pharmaceutical Preparations
Colonic Neoplasms
Breast Neoplasms

Keywords

  • Biomarker
  • FDG-PET
  • Lapatinib
  • Pharmacodynamics
  • Phase I

ASJC Scopus subject areas

  • Oncology

Cite this

Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. / Kawada, Kenji; Murakami, Koji; Sato, Takashi; Kojima, Yoshiki; Ebi, Hiromichi; Mukai, Hirofumi; Tahara, Makoto; Shimokata, Kaoru; Minami, Hironobu.

In: Japanese Journal of Clinical Oncology, Vol. 37, No. 1, 01.2007, p. 44-48.

Research output: Contribution to journalArticle

Kawada, Kenji ; Murakami, Koji ; Sato, Takashi ; Kojima, Yoshiki ; Ebi, Hiromichi ; Mukai, Hirofumi ; Tahara, Makoto ; Shimokata, Kaoru ; Minami, Hironobu. / Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. In: Japanese Journal of Clinical Oncology. 2007 ; Vol. 37, No. 1. pp. 44-48.
@article{60a75da03bf64ebe9fa33156d7fe83c9,
title = "Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors",
abstract = "Background: To evaluate the role of FDG-PET in assessing anti-tumor efficacy of molecular targeted drugs, we prospectively performed FDG-PET and CT for response evaluation in patients treated with lapatinib, a dual inhibitor of ErbB1 and ErbB2 tyrosine kinases. Methods: Lapatinib was given orally once a day at doses ranging from 1200 to 1800 mg in a phase I study. CT and FDG-PET were performed before treatment, and at 1, 2 and 3 months after the initiation of the treatment and every 2 months thereafter. Results: A total of 29 FDG-PET examinations were performed in eight patients with various solid tumors and the metabolic activity in the tumor was evaluated as SUVmax. The best responses, as assessed by CT, were as follows; one partial response, four stable disease and three disease progression. The partial response was observed in a patient with trastuzumab-resistant breast cancer, whose SUVmax was decreased by 60{\%} from baseline. In all of the four patients whose best response was stable disease, the SUVmax was decreased by 6-42{\%} one month after the start of treatment. Prolonged stable disease (10 months) was observed in a patient with colon cancer, whose SUVmax was decreased by 42{\%}. In the patient group with disease progression, SUVmax was increased in two out of three patients. Conclusions: FDG-PET detected decreases in the metabolic activity of the tumors in patients who experienced clinical benefits on treatment with lapatinib. Thus, FDG-PET may be useful for the evaluation of molecular targeted drugs, such as lapatinib.",
keywords = "Biomarker, FDG-PET, Lapatinib, Pharmacodynamics, Phase I",
author = "Kenji Kawada and Koji Murakami and Takashi Sato and Yoshiki Kojima and Hiromichi Ebi and Hirofumi Mukai and Makoto Tahara and Kaoru Shimokata and Hironobu Minami",
year = "2007",
month = "1",
doi = "10.1093/jjco/hyl116",
language = "English",
volume = "37",
pages = "44--48",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors

AU - Kawada, Kenji

AU - Murakami, Koji

AU - Sato, Takashi

AU - Kojima, Yoshiki

AU - Ebi, Hiromichi

AU - Mukai, Hirofumi

AU - Tahara, Makoto

AU - Shimokata, Kaoru

AU - Minami, Hironobu

PY - 2007/1

Y1 - 2007/1

N2 - Background: To evaluate the role of FDG-PET in assessing anti-tumor efficacy of molecular targeted drugs, we prospectively performed FDG-PET and CT for response evaluation in patients treated with lapatinib, a dual inhibitor of ErbB1 and ErbB2 tyrosine kinases. Methods: Lapatinib was given orally once a day at doses ranging from 1200 to 1800 mg in a phase I study. CT and FDG-PET were performed before treatment, and at 1, 2 and 3 months after the initiation of the treatment and every 2 months thereafter. Results: A total of 29 FDG-PET examinations were performed in eight patients with various solid tumors and the metabolic activity in the tumor was evaluated as SUVmax. The best responses, as assessed by CT, were as follows; one partial response, four stable disease and three disease progression. The partial response was observed in a patient with trastuzumab-resistant breast cancer, whose SUVmax was decreased by 60% from baseline. In all of the four patients whose best response was stable disease, the SUVmax was decreased by 6-42% one month after the start of treatment. Prolonged stable disease (10 months) was observed in a patient with colon cancer, whose SUVmax was decreased by 42%. In the patient group with disease progression, SUVmax was increased in two out of three patients. Conclusions: FDG-PET detected decreases in the metabolic activity of the tumors in patients who experienced clinical benefits on treatment with lapatinib. Thus, FDG-PET may be useful for the evaluation of molecular targeted drugs, such as lapatinib.

AB - Background: To evaluate the role of FDG-PET in assessing anti-tumor efficacy of molecular targeted drugs, we prospectively performed FDG-PET and CT for response evaluation in patients treated with lapatinib, a dual inhibitor of ErbB1 and ErbB2 tyrosine kinases. Methods: Lapatinib was given orally once a day at doses ranging from 1200 to 1800 mg in a phase I study. CT and FDG-PET were performed before treatment, and at 1, 2 and 3 months after the initiation of the treatment and every 2 months thereafter. Results: A total of 29 FDG-PET examinations were performed in eight patients with various solid tumors and the metabolic activity in the tumor was evaluated as SUVmax. The best responses, as assessed by CT, were as follows; one partial response, four stable disease and three disease progression. The partial response was observed in a patient with trastuzumab-resistant breast cancer, whose SUVmax was decreased by 60% from baseline. In all of the four patients whose best response was stable disease, the SUVmax was decreased by 6-42% one month after the start of treatment. Prolonged stable disease (10 months) was observed in a patient with colon cancer, whose SUVmax was decreased by 42%. In the patient group with disease progression, SUVmax was increased in two out of three patients. Conclusions: FDG-PET detected decreases in the metabolic activity of the tumors in patients who experienced clinical benefits on treatment with lapatinib. Thus, FDG-PET may be useful for the evaluation of molecular targeted drugs, such as lapatinib.

KW - Biomarker

KW - FDG-PET

KW - Lapatinib

KW - Pharmacodynamics

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=34447631719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447631719&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyl116

DO - 10.1093/jjco/hyl116

M3 - Article

C2 - 17060407

AN - SCOPUS:34447631719

VL - 37

SP - 44

EP - 48

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 1

ER -